Aligos therapeutics announces research collaboration and development agreement with xiamen amoytop biotech co. ltd. for use of aligos' oligonucleotide platform for the treatment of liver diseases

South san francisco, calif., may 12, 2023 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”, the “company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a research collaboration and development agreement with xiamen amoytop biotech co. ltd. (“amoytop”) for the use of aligos' oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the greater china territory.
ALGS Ratings Summary
ALGS Quant Ranking